UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study

Archives of virology, 2021-04, Vol.166 (4), p.1125-1131

2021

Volltextzugriff (PDF)

Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2020-01, Vol.26 (1), p.18-22

2020

Volltextzugriff (PDF)

Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections

Pharmaceutics, 2022-09, Vol.14 (9), p.1882

2022

Volltextzugriff (PDF)

Visceral leishmaniasis in a patient with active HBV/HDV co-infection

Journal of infection and public health, 2020-02, Vol.13 (2), p.306-308

2020

Volltextzugriff (PDF)

Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context

Biomedicines, 2021-09, Vol.9 (10), p.1288

2021

Volltextzugriff (PDF)

Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy

Pharmaceuticals (Basel, Switzerland), 2022-03, Vol.15 (3), p.355

2022

Volltextzugriff (PDF)

Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients

Antiviral research, 2013-10, Vol.100 (1), p.114-119

2013

Volltextzugriff (PDF)

Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment

Therapeutic drug monitoring, 2012-04, Vol.34 (2), p.165-170

2012

Volltextzugriff (PDF)

Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment

Therapeutic drug monitoring, 2012-12, Vol.34 (6), p.722-728

2012

Volltextzugriff (PDF)

Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir

Journal of pharmacy & pharmaceutical sciences, 2015-01, Vol.18 (2), p.171

2015

Volltextzugriff (PDF)

Twelve-Week Treatment of Acute Hepatitis C Virus with Pegylated Interferon-α-2b in Injection Drug Users

Clinical infectious diseases, 2007-09, Vol.45 (5), p.583-588

2007

Volltextzugriff (PDF)

Combination therapy in chronic hepatitis B: what are the real benefits?

Minerva medica, 2018-04, Vol.109 (2)

2018

Volltextzugriff (PDF)

Role of plasmatic and urinary TDF and TAF concentration in a cohort of HBV chronic hepatitis patients

Journal of hepatology, 2022-07, Vol.77, p.S825-S826

2022

Volltextzugriff (PDF)

ERRATUM Drug-drug interactions in anti-HCV therapy: a comparison among options available in Italy

Le infezioni in medicina, 2019-12, Vol.27 (4), p.481-481

2019

Volltextzugriff (PDF)

Drug-drug interactions in anti-HCV therapy: a comparison among options available in Italy

Le infezioni in medicina, 2019-09, Vol.27 (3), p.239-250

2019

Volltextzugriff (PDF)

Prospective evaluation of qHBsAg decline in patients affected by chronic hepatitis B, E genotype, treated with entecavir or tenofovir

Journal of hepatology, 2020-08, Vol.73, p.S872-S873

2020

Volltextzugriff (PDF)

SAT443 - Prospective evaluation of qHBsAg decline in patients affected by chronic hepatitis B, E genotype, treated with entecavir or tenofovir

Journal of hepatology, 2020-08, Vol.73, p.S872-S873

2020

Volltextzugriff (PDF)

Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B

Journal of medical virology, 2016-11, Vol.88 (11), p.1953-1959

2016

Volltextzugriff (PDF)

Extended duration of treatment with peginterferon alfa‐2a in patients with chronic hepatitis B, HBeAg‐negative and E genotype: A retrospective analysis

Journal of medical virology, 2018-06, Vol.90 (6), p.1047-1052

2018

Volltextzugriff (PDF)

Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis

Journal of medical virology, 2019-07, Vol.91 (7), p.1329-1334

2019

Volltextzugriff (PDF)

Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease

Archives of gynecology and obstetrics, 2018-12, Vol.298 (6), p.1205-1210

2018

Volltextzugriff (PDF)

Long-term reliability of fractioned CO2 laser as a treatment for vulvovaginal atrophy (VVA) symptoms

Archives of gynecology and obstetrics, 2017-11, Vol.296 (5), p.973-978

2017

Volltextzugriff (PDF)

Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B: Sequential Treatment of CHB

Journal of medical virology, 2016-11, Vol.88 (11), p.1953-1959

2016

Volltextzugriff (PDF)

1 – 25 von 113

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)
Mit Volltextzugriff
(96)

Publikationsform

Artikel
(112)
Berichte
(1)

Sprache

Englisch
(109)
Koreanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(81)
Science & Technology
(81)
Humans
(72)
Female
(57)
Male
(57)
Adult
(48)
Middle Aged
(47)
Treatment Outcome
(38)
Antiviral Agents - Therapeutic Use
(36)
Infectious Diseases
(35)
Pharmacology & Pharmacy
(31)
Genotype
(28)
Interferon-Alpha - Therapeutic Use
(28)
Hepatitis C, Chronic - Drug Therapy
(27)
Biological And Medical Sciences
(22)
Hepatitis C
(22)
Medical Sciences
(22)
Retrospective Studies
(22)
Hepacivirus - Genetics
(20)
Virology
(20)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study

Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders

Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections

Visceral leishmaniasis in a patient with active HBV/HDV co-infection

Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context

High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients

Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy

Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients

Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment

Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment

Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir

Twelve-Week Treatment of Acute Hepatitis C Virus with Pegylated Interferon-α-2b in Injection Drug Users

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study

Combination therapy in chronic hepatitis B: what are the real benefits?

Role of plasmatic and urinary TDF and TAF concentration in a cohort of HBV chronic hepatitis patients

ERRATUM Drug-drug interactions in anti-HCV therapy: a comparison among options available in Italy

Drug-drug interactions in anti-HCV therapy: a comparison among options available in Italy

Prospective evaluation of qHBsAg decline in patients affected by chronic hepatitis B, E genotype, treated with entecavir or tenofovir

SAT443 - Prospective evaluation of qHBsAg decline in patients affected by chronic hepatitis B, E genotype, treated with entecavir or tenofovir

Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B

Extended duration of treatment with peginterferon alfa‐2a in patients with chronic hepatitis B, HBeAg‐negative and E genotype: A retrospective analysis

Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis

Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease

Long-term reliability of fractioned CO2 laser as a treatment for vulvovaginal atrophy (VVA) symptoms

Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B: Sequential Treatment of CHB

Suchergebnisse filtern